Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial
- PMID: 33091147
- DOI: 10.1111/eci.13424
Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial
Comment on
-
Colchicine in Patients with Chronic Coronary Disease.N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31. N Engl J Med. 2020. PMID: 32865380 Clinical Trial.
References
REFERENCES
-
- Virchow R. Cellular Pathology as Based Upon Physiological and Pathological Histology. London: John Churchill; 1858.
-
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.
-
- Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752-762.
-
- Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782-1791.
-
- Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical